Menu ×


Diabetic Retinopathy Drugs Market Segmentation by Condition Type (Proliferative, and Non-Proliferative DR); by Treatment (Anti-VEGF Therapy, Laser Surgery, Intraocular Steroid Injection, and Vitreoretinal Surgery); by End User (Hospitals, Ophthalmic Clinics, and Ambulatory Surgical Centers)– Global Demand Analysis & Opportunity Outlook 2029

  • Report ID: 99
  • Text Size:

Extensive insights into the Growth of Diabetic Retinopathy Drug Market amidst COVID-19

Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.

Request Insights

Diabetic Retinopathy Drugs Market Highlights 2020 – 2029

The diabetic retinopathy market is estimated to garner a colossal revenue by growing at a noteworthy CAGR over the forecast period, i.e., 2021 – 2029. The growth of the market can be attributed to the rising prevalence of type 1 and type 2 diabetes, growing technological advancements in terms of developing effective retinopathy treatment and increasing geriatric population around the globe. According to the World Health Organization (WHO), 422 million people worldwide are suffering from diabetes. Along with these, availability of favorable health insurance policies for ophthalmologic surgeries in developed nations is also a significant factor expected to drive market growth in the coming years. Furthermore, growing adoption of minimal pain-inducing laser procedures is projected to offer lucrative opportunities to the market during the forecast period.

The market is bifurcated by condition type into proliferative and non-proliferative DR, out of which, the non-proliferative DR segment is anticipated to hold the largest share in the diabetic retinopathy market on account of the commonness of this disorder and the abundant presence of medical resources required to control this condition at an early stage. However, the segment for proliferative DR is assessed to grow at a higher rate owing to the increasing population reaching the advanced stages of retinopathy. Additionally, on the basis of treatment, the anti-VEGF therapy acquired a substantial market share in the recent years and is evaluated to continue this trend over the forecast period. This can be credited to the high usage of anti-VEGF drugs in treating mild to moderate cases of non-proliferative DR, and rapid recovery rates.

Diabetic Retinopathy Drugs Market Graph

Get more information on this report: Download Sample PDF

Global Diabetic Retinopathy Market Regional Synopsis

Regionally, the diabetic retinopathy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. The market in North America occupied the largest share over the forecast period on the back of supportive reimbursement policies covering treatment costs, sophisticated healthcare infrastructure and allocation of substantial healthcare expenditure by government. In addition to this, Europe is the second largest shareholder in the market attributing to the increasing obese population in the region, who are prone to diabetes and other related vision disorders. It is calculated that around 3-4% of Europeans are diagnosed with diabetic retinopathy every year. Moreover, the market in Asia Pacific is predicted to witness a notable growth during the forecast period as a result of a huge patient pool, growing elderly populace and the rise in innovations for treatment of diabetic retinopathy. The growth of the market in this region is expected to be steered majorly by nations such as China and Japan owing to the escalating per capita income and significant developments in the medical sector.

Diabetic Retinopathy Market Share Image

The diabetic retinopathy market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the diabetic retinopathy market includes the following segments:

By Condition Type

  • Proliferative DR
  • Non-Proliferative DR

By Treatment

  • Anti-VEGF Therapy
  • Laser Surgery
  • Intraocular Steroid Injection
  • Vitreoretinal Surgery

By End User

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

Growth Drivers

  • Increasing Prevalence of Diabetes to Drive Market Growth
  • Rising Technological Advancements Associated with Diabetic Retinopathy Treatment to Expand Market


  • Lack of Trained Ophthalmologists in Low Income Economies Restraining Market Growth

Top Featured Companies Dominating the Market

  • Pfizer Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals Inc
  • Abbott Laboratories
  • Novartis AG
  • Bausch Health Companies Inc.
  • Ampio Pharmaceuticals Inc.
  • Oxurion NV


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved